Recor Medical Champions Global Action on World Hypertension Day: Early Intervention and Continued Innovation Crucial in Tackling This Silent Killer Impacting Billions Worldwide
May 17 2024 - 9:00AM
Hypertension, or high blood pressure, affects nearly half of all
Americans and more than one billion people worldwide.
Hypertension is known as the “silent killer” because many
people do not know they have it and, over time, it can lead to
serious health issues. Hypertension is the number one contributor
to the burden of human disease globally, has been associated with a
five-year reduction in life expectancy and is a major risk factor
for heart disease, stroke, heart attacks and other serious health
problems.
May 17 is World Hypertension Day, a global initiative to
highlight the importance of monitoring blood pressure and provide
education about this devastating chronic disease. Recor
Medical – the pioneer of the Paradise™ Ultrasound Renal Denervation
(uRDN) System, a recently FDA-approved medical device-based
procedure to treat hypertension – is joining the fight by promoting
awareness and encouraging continued innovation and equitable access
to early intervention and sustainable solutions for patients
suffering from this chronic disease.
According to a report from the World Health Organization, the
number of adults with hypertension doubled between 1990 and 2019
from 650 million to 1.3 billion. The report also states that only
54 percent of adults with hypertension are diagnosed and only 42
percent receive treatment. Furthermore, left undetected or
uncontrolled, hypertension is a leading contributor to other
long-term risks, including:
- Chronic kidney
disease or failure
- Vision loss
- Sexual
dysfunction
- Dementia
- Uterine
fibroids.
About one-third of the patients who are treated for hypertension
remain uncontrolled despite making healthy lifestyle changes and
taking more than three medications. For these patients, innovation
and investment in new solutions are vital to achieve blood pressure
control and realize a healthier future. From pharmaceutical
treatments to technology, patients need new therapies that can
provide life-changing results. This includes medical device-based
therapies, like the Paradise™ Ultrasound Renal Denervation (uRDN)
system, an additional treatment option for patients who remain
uncontrolled and at elevated cardiovascular risk despite
standard lifestyle changes and treatment with oral
medications.
“While new technologies like Recor’s Paradise uRDN system are
helping patients in the fight against hypertension and making a
significant impact on people’s lives, we know education, early
intervention and hypertension management are critical first steps
to treating this chronic disease,” said Lara Barghout, President
and CEO of Recor Medical. “We support the efforts of World
Hypertension Day and will continue to advocate with providers and
for patients to mitigate the effects of this disease before it
progresses.”
“Physicians and their patients who struggle with hypertension
are in need of innovative solutions. And, for those with
uncontrolled resistant hypertension, technology is becoming an
increasingly important option to help control this disease. All
interventions need to be considered to tackle this global problem,”
Barghout added.
Recor Medical’s Paradise uRDN system is a first-of-its-kind
ultrasound-based renal denervation (RDN) technology designed to
lower blood pressure by denervating overactive sympathetic nerves
surrounding the renal arteries. Paradise uRDN delivers two to three
doses of 360-degree ultrasound energy — lasting seven seconds each
— through each of the main renal arteries to the surrounding
nerves. The Paradise catheter features the exclusive HydroCooling™
system, which circulates sterile water through the balloon during
the procedure to help cool and protect the inner layers of the
renal artery.
About Recor Medical, Inc.Recor Medical, headquartered in
Palo Alto, Calif., a wholly owned subsidiary of Otsuka Medical
Devices Co., Ltd., is a medical technology company focused on
transforming the management of hypertension. Recor has pioneered
the use of the Paradise Ultrasound Renal Denervation system for the
treatment of hypertension. The Paradise system is an
investigational device in Japan, is FDA approved in the United
States, and bears the CE mark. Recor has reported positive outcomes
in three independent, randomized, sham-controlled studies of the
Paradise system in patients with mild-to-moderate and resistant
hypertension. In addition, Recor has begun the Global Paradise
System (“GPS”) Registry in the European Union and the UK, with
plans to expand globally.http://www.recormedical.com/
About Otsuka Medical DevicesOtsuka Medical Devices Co.,
Ltd. engages in the global development and commercialization of
medical devices that provide new therapeutic options in areas where
patient needs cannot be met through pharmaceutical or other
conventional treatment. Otsuka Medical Devices is a subsidiary of
Otsuka Holdings Co., Ltd. (www.otsuka.com/en), a global healthcare
company listed on the Tokyo Stock Exchange (JP
4578).https://www.omd.otsuka.com/en/
# # #Media Contact:Lisa OwensThe Mullings
Grouplowens@mullingsgroup.com+1-210-601-6647
- Hypertension affects nearly half of all Americans and more than
one billion people worldwide.
- Today is World Hypertension Day
Lara Barghout
Recor Medical
+1 650 542 7700
lara.barghout@recormedical.com